Cargando…

Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas

Background: For peripheral T-cell lymphomas (PTCLs) patients, high-dose therapy combined with autologous peripheral blood stem cell transplantation (HDT/ASCT) has been an alternative treatment option, due to the lack of efficacy from conventional chemotherapy. While not all PTCLs could have benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Meng, Wang, Xiaopei, Xie, Yan, Liu, Weiping, Zhang, Chen, Ping, Lingyan, Ying, Zhitao, Deng, Lijuan, Zheng, Wen, Lin, Ningjing, Tu, Meifeng, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036090/
https://www.ncbi.nlm.nih.gov/pubmed/30008598
http://dx.doi.org/10.7150/ijms.23067
_version_ 1783338101046771712
author Wu, Meng
Wang, Xiaopei
Xie, Yan
Liu, Weiping
Zhang, Chen
Ping, Lingyan
Ying, Zhitao
Deng, Lijuan
Zheng, Wen
Lin, Ningjing
Tu, Meifeng
Song, Yuqin
Zhu, Jun
author_facet Wu, Meng
Wang, Xiaopei
Xie, Yan
Liu, Weiping
Zhang, Chen
Ping, Lingyan
Ying, Zhitao
Deng, Lijuan
Zheng, Wen
Lin, Ningjing
Tu, Meifeng
Song, Yuqin
Zhu, Jun
author_sort Wu, Meng
collection PubMed
description Background: For peripheral T-cell lymphomas (PTCLs) patients, high-dose therapy combined with autologous peripheral blood stem cell transplantation (HDT/ASCT) has been an alternative treatment option, due to the lack of efficacy from conventional chemotherapy. While not all PTCLs could have benefit in survival from HDT/ASCT. The aim of this study was to evaluate the value of high-dose therapy combined with autologous peripheral blood stem cell transplantation (HDT/ASCT) in Chinese patients with Peripheral T-cell Lymphomas (PTCLs), in order to determine the cohort most suitable to receive HDT/ASCT. Methods: A total of 79 patients with PTCLs who received HDT/ASCT in Peking University Cancer Hospital & Institute from January 2001 to august 2016 were retrospectively analyzed. Results: At a median follow-up time of 23.6 months, the 2-year progression-free survival (PFS) and 2-year overall survival (OS) of the entire cohort were 75.2% and 83.6% respectively. Patients with first complete remission (CR1) (2-year PFS 85.8%, 2-year OS 94.2%) were superior to others in survival. Patients with second complete remission (CR2) had no advantage in survival compared with those with first partial remission (PR1) (2-year PFS: 43.8% vs. 76.2%, p=0.128; 2-year OS: 72.9% vs. 77.1%, p=0.842). In multivariate analysis, response before HDT/ASCT (p=0.001) and LDH before HDT/ASCT (p=0.047) were highly predictive for PFS, while no factors could independently predict OS. Subgroup analysis revealed that HDT/ASCT could improve the survival of patients with angioimmunoblastic T-cell lymphoma (AITL), especially in patients with chemosensitivity. Patients with natural killer / T-cell lymphoma (NKTCL) who received HDT/ASCT with CR1 also had benefit in survival from HDT/ASCT, while nearly 90% of non-CR1 patients appeared bone marrow involvement after HDT/ASCT. Conclusion: Patients who achieved complete remission after first-line therapy, especially with AITL and NKTCL, should strongly be recommended to receive HDT/ASCT. The future prospective trial is warranted.
format Online
Article
Text
id pubmed-6036090
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-60360902018-07-15 Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas Wu, Meng Wang, Xiaopei Xie, Yan Liu, Weiping Zhang, Chen Ping, Lingyan Ying, Zhitao Deng, Lijuan Zheng, Wen Lin, Ningjing Tu, Meifeng Song, Yuqin Zhu, Jun Int J Med Sci Research Paper Background: For peripheral T-cell lymphomas (PTCLs) patients, high-dose therapy combined with autologous peripheral blood stem cell transplantation (HDT/ASCT) has been an alternative treatment option, due to the lack of efficacy from conventional chemotherapy. While not all PTCLs could have benefit in survival from HDT/ASCT. The aim of this study was to evaluate the value of high-dose therapy combined with autologous peripheral blood stem cell transplantation (HDT/ASCT) in Chinese patients with Peripheral T-cell Lymphomas (PTCLs), in order to determine the cohort most suitable to receive HDT/ASCT. Methods: A total of 79 patients with PTCLs who received HDT/ASCT in Peking University Cancer Hospital & Institute from January 2001 to august 2016 were retrospectively analyzed. Results: At a median follow-up time of 23.6 months, the 2-year progression-free survival (PFS) and 2-year overall survival (OS) of the entire cohort were 75.2% and 83.6% respectively. Patients with first complete remission (CR1) (2-year PFS 85.8%, 2-year OS 94.2%) were superior to others in survival. Patients with second complete remission (CR2) had no advantage in survival compared with those with first partial remission (PR1) (2-year PFS: 43.8% vs. 76.2%, p=0.128; 2-year OS: 72.9% vs. 77.1%, p=0.842). In multivariate analysis, response before HDT/ASCT (p=0.001) and LDH before HDT/ASCT (p=0.047) were highly predictive for PFS, while no factors could independently predict OS. Subgroup analysis revealed that HDT/ASCT could improve the survival of patients with angioimmunoblastic T-cell lymphoma (AITL), especially in patients with chemosensitivity. Patients with natural killer / T-cell lymphoma (NKTCL) who received HDT/ASCT with CR1 also had benefit in survival from HDT/ASCT, while nearly 90% of non-CR1 patients appeared bone marrow involvement after HDT/ASCT. Conclusion: Patients who achieved complete remission after first-line therapy, especially with AITL and NKTCL, should strongly be recommended to receive HDT/ASCT. The future prospective trial is warranted. Ivyspring International Publisher 2018-06-04 /pmc/articles/PMC6036090/ /pubmed/30008598 http://dx.doi.org/10.7150/ijms.23067 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Wu, Meng
Wang, Xiaopei
Xie, Yan
Liu, Weiping
Zhang, Chen
Ping, Lingyan
Ying, Zhitao
Deng, Lijuan
Zheng, Wen
Lin, Ningjing
Tu, Meifeng
Song, Yuqin
Zhu, Jun
Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
title Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
title_full Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
title_fullStr Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
title_full_unstemmed Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
title_short Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
title_sort outcome and prospective factor analysis of high-dose therapy combined with autologous peripheral blood stem cell transplantation in patients with peripheral t-cell lymphomas
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036090/
https://www.ncbi.nlm.nih.gov/pubmed/30008598
http://dx.doi.org/10.7150/ijms.23067
work_keys_str_mv AT wumeng outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT wangxiaopei outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT xieyan outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT liuweiping outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT zhangchen outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT pinglingyan outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT yingzhitao outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT denglijuan outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT zhengwen outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT linningjing outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT tumeifeng outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT songyuqin outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas
AT zhujun outcomeandprospectivefactoranalysisofhighdosetherapycombinedwithautologousperipheralbloodstemcelltransplantationinpatientswithperipheraltcelllymphomas